Insider Transactions in Q2 2021 at Verve Therapeutics, Inc. (VERV)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 21
2021
|
Arch Venture Partners X, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,508,809
+50.0%
|
-
|
|
Jun 21
2021
|
Broad Institute, Inc. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
387,830
+32.38%
|
-
|
|
Jun 21
2021
|
Fmr LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,037,294
+48.27%
|
-
|
|
Jun 21
2021
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
275,000
+21.84%
|
$5,225,000
$19.0 P/Share
|
|
Jun 21
2021
|
Cormorant Asset Management, LP |
BUY
Conversion of derivative security
|
Indirect |
709,224
+50.0%
|
-
|
|
Jun 21
2021
|
Beam Therapeutics Inc. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
270,895
+33.12%
|
-
|
|
Jun 21
2021
|
Redmile Group, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,050,000
+35.16%
|
$19,950,000
$19.0 P/Share
|
|
Jun 21
2021
|
Redmile Group, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
886,530
+50.0%
|
-
|
|
Jun 21
2021
|
Casdin Partners Master Fund, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,100,000
+31.27%
|
$20,900,000
$19.0 P/Share
|
|
Jun 21
2021
|
Casdin Partners Master Fund, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,317,596
+34.53%
|
-
|
|
Jun 21
2021
|
Casdin Private Growth Equity Fund, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
620,571
+50.0%
|
-
|
|
Jun 21
2021
|
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,495,571
+40.8%
|
-
|
|
Jun 21
2021
|
Krishna Yeshwant |
BUY
Conversion of derivative security
|
Indirect |
10,793,414
+36.34%
|
-
|
|
Jun 21
2021
|
Gv 2019 Gp, L.L.C. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
4,472,509
+29.51%
|
-
|
|
Jun 21
2021
|
Gv 2017 Gp, L.L.C. |
BUY
Conversion of derivative security
|
Indirect |
6,320,905
+50.0%
|
-
|
|
Jun 21
2021
|
Novo Holdings > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
350,000
+30.61%
|
$6,650,000
$19.0 P/Share
|
|
Jun 21
2021
|
Novo Holdings > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
443,265
+50.0%
|
-
|
|
Jun 21
2021
|
Logos Global Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
370,000
+50.0%
|
$7,030,000
$19.0 P/Share
|
|
Jun 21
2021
|
Logos Global Management LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
443,265
+50.0%
|
-
|
|
Jun 21
2021
|
Rock Springs Capital Management LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
709,224
+50.0%
|
-
|
|
Jun 21
2021
|
Rock Springs Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
370,000
+28.54%
|
$7,030,000
$19.0 P/Share
|
|
Jun 21
2021
|
Sekar Kathiresan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+0.61%
|
$47,500
$19.0 P/Share
|
|
Jun 21
2021
|
Andrew Bellinger Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$95,000
$19.0 P/Share
|
|
Jun 21
2021
|
Margaret Beaudoin Vice President, Finance |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$19,000
$19.0 P/Share
|